What baseline laboratory tests are needed before initiating isotretinoin (Accutane) therapy?

Baseline Laboratory Testing for Isotretinoin (Accutane)

Before starting isotretinoin, obtain pregnancy testing (for patients with pregnancy potential), liver function tests (ALT/AST), and a fasting lipid panel (triglycerides and cholesterol); complete blood count monitoring is not recommended. 1, 2

Required Baseline Tests

Pregnancy Testing (Patients with Pregnancy Potential)

• Two negative pregnancy tests are mandatory before the first prescription, with sensitivity of at least 25 mIU/mL 2
• The first test is a screening test obtained when deciding to pursue isotretinoin 2
• The second test must be performed in a CLIA-certified laboratory, with at least 19 days between the two tests 2
• For patients with regular menstrual cycles: perform the second test during the first 5 days of the menstrual period immediately before starting therapy, after using 2 forms of contraception for 1 month 2
• For patients with amenorrhea or irregular cycles: perform the second test immediately before starting therapy, after using 2 forms of contraception for 1 month 2

Liver Function Tests

• Obtain ALT and AST at baseline 3, 1, 4
• The American Academy of Dermatology recommends checking liver enzymes before initiation 3
• Abnormal liver function tests occur in only 0.8%-10.4% of patients, with only 0.9%-4.7% requiring drug discontinuation 3, 1

Lipid Panel

• Obtain fasting triglycerides and cholesterol at baseline 3, 1, 2
• Patients should fast and avoid alcohol for at least 36 hours before testing 2
• Triglyceride abnormalities occur in 7.1%-39% of patients, substantially higher than liver enzyme elevations 3, 1
• Cholesterol abnormalities occur in 6.8%-27.2% of patients 1

Tests NOT Recommended at Baseline

Complete Blood Count

• The American Academy of Dermatology explicitly does not recommend CBC monitoring during isotretinoin treatment 1
• Abnormal platelet levels occur in only 1.2%-2.9% of patients 1
• Mild anemia occurs in only 0.4% of patients 1
• White blood cell abnormalities (7.0%-10.8%) are clinically insignificant 1
• Expert consensus confirms routine CBC monitoring is unnecessary 5, 4, 6

Other Unnecessary Tests

• Do not check gamma-glutamyl transferase, bilirubin, albumin, total protein, LDL, HDL, or C-reactive protein 5
• Do not check basic metabolic panel parameters 5

Follow-Up Monitoring Schedule

Standard Monitoring (Low-Risk Patients)

• Recheck liver enzymes and lipids at 2 months (at peak dose), then only as clinically indicated 3, 4
• The American Academy of Dermatology recommends a single follow-up at 2 months once treatment dose is established 3
• Monthly monitoring is explicitly unwarranted in low-risk patients 3
• Monthly pregnancy testing is required throughout therapy for patients with pregnancy potential 2

High-Risk Patients Requiring More Frequent Monitoring

• Check liver enzymes and lipids every 2-4 weeks initially, then every 3 months for patients with: 3
  • Pre-existing liver disease
  • Concurrent hepatotoxic medications
  • History of excess alcohol intake
  • Obesity or diabetes (increased risk of hypertriglyceridemia and fatty liver)
  • Dose adjustments or changes

Common Pitfalls to Avoid

• Do not order routine monthly labs in healthy patients with normal baseline values—this represents unnecessary testing that contradicts current guidelines 3, 4
• Do not continue isotretinoin if triglycerides exceed 400 mg/dL due to acute pancreatitis risk 3
• Stop all non-essential hepatotoxic medications and supplements (protein powders, creatine, herbal extracts) before starting therapy 3
• Ensure patients avoid St. John's Wort, which may decrease hormonal contraceptive effectiveness 2
• For Grade 2-3 liver enzyme elevations (AST/ALT 3-20× upper limit of normal): temporarily discontinue isotretinoin and monitor weekly until normalization 3
• For Grade 4 elevations (AST/ALT >20× upper limit of normal): permanently discontinue and refer immediately to hepatology 3